Monthly Archives: August 2013

GAINing Ground in Antibiotics

GAIN

With the rise of antibiotic resistant “superbugs” in recent years, everyone agrees there is an urgent need to develop new and effective antibiotics. One measure designed to spur such development is the Generating Antibiotics Incentives Now (GAIN) Act, which was enacted last year. The law provides an additional five years of market exclusivity and priority FDA review for innovative antibiotics that target qualifying pathogens. Much of the current research in the field is being done Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , ,

When Crop Vandalism Kills Children…

Golden Rice

In the days following the senseless destruction of Golden Rice field trials in the Philippines that occurred earlier this month, there has been much response on social media and in the blogosphere. “Our Golden Rice research is part of our humanitarian work to reduce vitamin A deficiency that mostly affects women and children – causing sickness, blindness, and even death,” said Dr. Bruce Tolentino, deputy director general of communications and partnerships at the International Rice Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Chinese In-Licensing Continues to Strengthen

Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are outpacing other forms of biotech deal-making in 2013. In fact, the number of in-licensing deals announced so far this year is more than the combined number of 2012 deals in out-licensing, JV/Alliance and M&A, according to BIO’s Industry Analysis research and GBI. This deal-making momentum bodes well for small and medium-sized biotech companies that have early-stage compounds under development in the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Fresenius v. Baxter: BIO files Amicus Brief in Federal Circuit

shutterstock_1092009

The Biotechnology Industry Organization filed an amicus brief at the Federal Circuit in the case of Fresenius v. Baxter: BIO is concerned that the panel decision could have a number of unintended consequences, such as incentivizing defendants (or declaratory judgment plaintiffs) to employ dilatory tactics in the federal courts while re-arguing already-decided issues under claim construction more favorable to the patent challenger and lower burden-of-proof standards in the PTO.  Courts and parties may be forced Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Investor Forum Company Snapshot: MAX BioPharma

maxbiopharma

Earlier this week, we featured a presenting company for our upcoming BIO Investor Forum event in San Francisco in our ‘company snapshot‘ feature. For our next post, we spoke to MAX BioPharma, who will be giving a presentation in our Discovery Company presentation track, which features companies in their Seed or Series A financing rounds, with under 25 million raised to date. Read on to learn more about this Discovery Company.   Company Snapshot What Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,